Company intelligence

MRKR

Marker Therapeutics, Inc. · NASDAQ · Healthcare

Price$1.09+4.81% · +$0.05

Market cap18.17MEquity value

P / E-2.3Trailing ratio

Volume445.07KLatest session

Market data

MRKR price chart

TradingView

Related signals

1 min delayed

Browse public MRKR signals with their source context and measured market impact. Open any signal for its permanent analysis page.

MRKRAug 26, 2025-15.70% since signal

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics updated on Phase 1 APOLLO study for MT-601. MT-601 demonstrated a 66% response rate in Non-Hodgkin Lymphoma patients. No dose-limiting toxicities were reported, indicating robust safety. Future updates on clinical data are expected in the first half of 2026. MRKR stock is currently down 14.28%, trading at $1.08.

View signal analysis

Research